Oncopeptides
Oncopeptides publishes disclosure document regarding rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) publishes disclosure document in connection with the Company’s new share issue with preferential rights for existing shareholders of approximately SEK 150 million, as resolved by the Board of Directors on 21 August 2025 by virtue of the authorization from the Annual General Meeting held on 22 May 2025 (the “Rights Issue”). The disclosure document has been registered with the Swedish Financial Supervisory Authority and is available at the Company’s website.
Disclosure document
In connection with the Rights Issue, the Company has prepared a disclosure document in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.
Today, Oncopeptides announces that the disclosure document has been registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website www.oncopeptides.com and on www.dnbcarnegie.se.
Preliminary timetable for the Rights Issue
The below timetable for the Rights Issue is preliminary and may be adjusted.
Record date for right to receive subscription rights | 28 August 2025 |
Trading in subscription rights | 1 – 10 September 2025 |
Subscription period | 1 – 15 September 2025 |
Trading in paid subscribed shares (BTA) | 1 – 22 September 2025 |
Announcement of the outcome of the Rights Issue | Around 17 September 2025 |
Advisors
DNB Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner in connection with the Rights Issue. Zonda Partners acts as Joint Bookrunner. Advokatfirman Vinge KB is legal adviser to the Company.
Datum | 2025-08-28, kl 08:15 |
Källa | MFN |
Oncopeptides publishes disclosure document regarding rights issue | |
Oncopeptides Bilaga IX Informationsdokument |
